List view / Grid view
Zealand has announced results from a clinical Phase I trial with a single-dose version of its novel, stable glucagon analogue, ZP4207.
20 November 2013 | By Zealand Pharma
Zealand Pharma A/S announces that the first patient has been treated in a Phase II Clinical Proof-of-Concept study of danegaptide...
16 June 2011 | By Boehringer Ingelheim
For dual-acting glucagon and GLP-1 receptor agonists...
9 December 2010 | By M:Communications
Zealand Pharma, today announces the receipt of a EUR 500,000 milestone payment as part of its license agreement with Helsinn Healthcare...
